Anaplastic astrocytomas: biology and treatment

References

• The Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J. Clin. Oncol.19, 509–518 (2001).
   PubMed Web of Science ®Google Scholar
• Prados MD, Scott C, Curran WJ et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of Radiation Therapy Oncology Group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J. Clin. Oncol.17, 3389–3395 (1999).
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncol.5(2), 79–88 (2003).
   PubMed Web of Science ®Google Scholar
• Prados MD, Levin V. Biology and treatment of malignant glioma. Semin. Oncology27(3 Suppl. 6), 1–10 (2000).
   PubMedGoogle Scholar
• Gutin PH, Prados MD, Phillips TL et al. External irradiation followed by an interstitial high activity iodine-125 implant “boost” in the initial treatment of malignant gliomas: NCOG Study 6G82–2. Int. J. Radiat. Oncol. Biol. Phys.21, 601 (1991).
   PubMed Web of Science ®Google Scholar
• Loeffler JS, Alexander E, Shea WM et al. Radiosurgery as part of the initial management of patients with malignant gliomas. J. Clin. Oncol.10(9), 1379–1385 (1992).
   PubMed Web of Science ®Google Scholar
• Prados MD, Gutin PH, Phillips TL et al. Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: the UCSF experience. Int. J. Radiat. Oncol. Biol. Phys.24, 593 (1992).
   PubMed Web of Science ®Google Scholar
• Levin VA, Silver P, Hannigan J et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic giomas: NCOG 6G61 final report. Int. J. Radiat. Oncol. Biol. Phys.18, 321–324 (1990).
   PubMed Web of Science ®Google Scholar
• Stewart LA. Chemotherapy in adult high-grade glioma: a systemic review and meta-analysis of individual patient data from 12 randomized trials. Lancet359, 1011–1018 (2002).
   PubMed Web of Science ®Google Scholar
• Fine HA, Dear KB, Loeffler JS et al. Meta-analysis of radiation therapy and without chemotherapy for malignant gliomas in adults. Cancer71, 2585–2597 (1993).
   PubMed Web of Science ®Google Scholar
• Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol.17, 2572–2578 (1999).
   PubMed Web of Science ®Google Scholar
• Yung WKA, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant gliomas: a Phase II study. J. Clin. Oncol.9, 860 (1991).
   PubMed Web of Science ®Google Scholar
• Allen JC, Walker R, Luks E et al. Carboplatin and recurrent childhood brain tumors. J. Clin. Oncol.759–763 (1987).
   Web of Science ®Google Scholar
• Yung WK, Prados MD, Yaya-Tur R et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J. Clin. Oncol.17, 2762–2771 (1999).
   PubMed Web of Science ®Google Scholar
• Allen JC, Helson L. High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J. Neurosurg.55, 749–756 (1981).
   PubMed Web of Science ®Google Scholar
• Longee DC, Friedman HS, Albright RE et al. Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J. Neurosurg.72, 583–588 (1990).
   PubMed Web of Science ®Google Scholar
• Prados MD, Gutin PH, Phillips TL et al. Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int. J. Radiat. Oncol. Biol. Phys.23, 3–8 (1992).
   PubMed Web of Science ®Google Scholar
• Tortosa A, Vinolas N, Villa S et al. Prognostic implications of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer97, 1063–1071 (2003).
   PubMed Web of Science ®Google Scholar
• Levin VA, Hess KR, Choucair A et al. Phase III randomized study of postradiotherapy chemotherapy with combination-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin. Cancer Res.9, 891–990 (2003).
   Google Scholar
• Chang SM, Seiferheld W, Curran W et al. Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. Int. J. Radiat. Oncol. Biol. Phys.59, 1122–1126 (2004).
   PubMed Web of Science ®Google Scholar
• Laramore GE, Martz KL, Nelson JS et al. Radiation Therapy Oncology Group (RTOG) survival data on anaplastic astrocytomas of the brain: does a more aggressive form of treatment adversely impact survival? Int. J. Radiat. Oncol. Biol. Phys.17(6), 1351–1356 (1989).
   PubMed Web of Science ®Google Scholar
• Prados MD, Seiferheld W, Sandler HM et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int. J. Radiat. Oncol. Biol. Phys.58, 1147–1152 (2004).
   PubMed Web of Science ®Google Scholar
• Levin VA, Prados MD, Yung WKA, Gleason MJ, Ictech S, Malec M. Treatment of recurrent gliomas with enflornithine. J. Natl Cancer Instit.84, 1432–1437 (1992).
   PubMedGoogle Scholar
• Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet345, 1008–1012 (1995).
   PubMed Web of Science ®Google Scholar
• Levin VA, Prados MD. Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosoureas resistance. J. Clin. Oncol.10, 766–771 (1992).
   PubMed Web of Science ®Google Scholar
• Yung WKA, Kyritsis AP, Gleason MJ, Levin VA. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin. Cancer Res.2, 1931–1935 (1996).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Kormanik P. Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas. J. Clin. Oncol.43, 71–78 (1999).
   Google Scholar
• Chamberlain M, Tsao-Wei D, Blumenthal D, Glantz MJ. Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma Cancer (2007) (In Press).
   PubMedGoogle Scholar
• Chamberlain MC, Tsao-Wei D, Groshen S. Salvage chemotherapy with cyclophosphamide for temozolomide refractory anaplastic astrocytoma. Cancer106(1), 172–179 (2006).
   PubMed Web of Science ®Google Scholar
• Pathology and genetics of tumors of the nervous system. In: World Health Organization Classification of Tumours of the Nervous System, Editorial and Consensus Conference Working Group. Kleihues P, Cavenee WK (Eds). IARC Press, Lyon, France (2007).
   Google Scholar
• Ironside JW, Moss TH, Louis DN et al. Diagnostic Pathology of Nervous System Tumours. Churchill Livingstone, London, UK (2002).
   Google Scholar
• Louis DN, Pomeroy SL, Cairncross JG. Focus on central nervous system neoplasia. Cancer Cell1(2), 125–128 (2002).
   PubMed Web of Science ®Google Scholar
• Louis DN, Cavenee WK. Molecular biology of central nervous system tumors. In: Cancer: Principles and Practice of Oncology (Seventh Edition). DeVita VT Jr, Hellman S, Rosenberg SA (Eds). Lippincott-Raven, PA, USA (2004).
   Google Scholar
• Louis DN. Molecular pathology of malignant glioma. Ann. Rev. Pathol. Mech. Dis.1, 97–124 (2006).
   PubMed Web of Science ®Google Scholar
• Stemmer-Rachamimov AO, Louis DN, Nielsen GP et al. Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res.64, 3718–3724 (2004).
   PubMed Web of Science ®Google Scholar
• Zhu Y, Guignard F, Zhao D et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell8, 119–130 (2005).
   PubMed Web of Science ®Google Scholar
• Galli R, Binda E, Orfanelli U et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res.64, 7011–7021 (2004).
   PubMed Web of Science ®Google Scholar
• Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumor initiating cells. Nature432, 396–401 (2004).
   PubMed Web of Science ®Google Scholar
• Watanabe K, Tachibana O, Sata K et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastoma. Brain Pathol.6, 217–223 (1996).
   PubMed Web of Science ®Google Scholar
• Ueki K, Ono Y, Henson JW et al. CDKN2/p16 or RB alterations occur in the majority of glioblastoma and are inversely correlated. Cancer Res.56, 150–153 (1996).
   PubMed Web of Science ®Google Scholar
• Fujisawa H, Kurrer M, Reis RM et al. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Am. J. Pathol.155, 387–394 (1999).
   PubMed Web of Science ®Google Scholar
• Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphastase gene mutated in human brain, breast and prostate cancer. Science275, 1943–1947 (1997).
   PubMed Web of Science ®Google Scholar
• Hermanson M, Funa K, Hartman M et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res.52, 3213–3219 (1992).
   PubMed Web of Science ®Google Scholar
• Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer3, 489–501 (2003).
   PubMed Web of Science ®Google Scholar
• Brat DJ, Mapstone TB. Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann. Intern. Med.138, 659–668 (2003).
   PubMed Web of Science ®Google Scholar
• Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab. Invest.84, 397–405 (2004).
   PubMed Web of Science ®Google Scholar
• Brat DJ, Castellano-Sanchez AA, Hunter SB et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res.64, 920–927 (2004).
   PubMed Web of Science ®Google Scholar
• Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med.343, 1350–1354 (2000).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Godard S et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res.10, 1841–1871 (2004).
   Google Scholar
• Hegi ME, Diserens AC, Gorlia T et al.MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352(10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Chang SM, Parney IF, Huang W et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA293, 557–564 (2005).
   PubMed Web of Science ®Google Scholar
• Kondziolka D, Bernstein M, Resch L et al. Significance of hemorrhage into brain tumors: clinicopathological study. J. Neurosurg.67, 852–860 (1987).
   PubMed Web of Science ®Google Scholar
• Yung WA, Horten BC, Shapiro WR. Meningeal gliomatosis: a review of 12 cases. Ann. Neurol.8, 605–609 (1980).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Combined-modality treatment of leptomeningeal gliomatosis. Neurosurgery52, 324–330 (2003).
   PubMed Web of Science ®Google Scholar
• Bragg DG, Osborn AG. CNS imaging of neoplasms. Int. J. Radiat. Oncol. Biol. Phys.21, 841–860 (1991).
   PubMed Web of Science ®Google Scholar
• Jaeckle KA. Neuroimaging for central nervous system tumors. Semin. Oncol.18, 150–158 (1991).
   PubMed Web of Science ®Google Scholar
• Brem SS, Bierman PJ, Black P et al. Central nervous system cancers: clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw.3, 644–690 (2005).
   PubMedGoogle Scholar
• Stupp R, Mason WP, van den Bent M et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352, 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Cairncross G, Berkey B, Shaw E et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Oncology Group trial 9402. J. Clin. Oncol.24(18), 2707–2714 (2006).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant procarbazine, lomustine and vincristine improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer Phase III trial. J. Clin. Oncol.24(18), 2715–2722 (2006).
   PubMed Web of Science ®Google Scholar
• Jaeckle KA, Hess KR, Yung WK et al. Phase II evaluation of temozolomide nd 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J. Clin. Oncol.21(12), 2305–2311 (2003).
   PubMed Web of Science ®Google Scholar
• Vrendenburgh JJ, Desjardins A, Herndon JE II et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res.13(4), 1253–1259 (2007).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, diTomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11, 83–95 (2007).
   PubMed Web of Science ®Google Scholar
• Nabors LB, Mikkelsen T, Rosenfeld SS et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol.25(13), 1651–1662 (2007).
   PubMed Web of Science ®Google Scholar
• Combs SE, Thilmann C, Edler L, Debus J, Schultz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J. Clin. Oncol.23(34), 8863–8869 (2005).
   PubMed Web of Science ®Google Scholar
• Ulm AJ, Friedman WA, Bradshaw P, Fote KD, Bova FJ. Radiosurgery in the management of malignant gliomas: the University of Florida experience. Neurosurgery57, 512–517 (2005).
   PubMed Web of Science ®Google Scholar
• Muller W, Afra D, Schroder R. Supratentorial recurrences of gliomas: morphological studies in relation to time intervals with astrocytomas. Acta Neurochir. (Wien)37, 75–84 (1977).
   PubMed Web of Science ®Google Scholar
• Laws ER, Taylor WF, Clifton MB et al. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J. Neurosurg.61, 665–673 (1984).
   PubMed Web of Science ®Google Scholar
• Piepmeier J, Christopher S, Spencer D et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery38, 872–878 (1996).
   PubMed Web of Science ®Google Scholar
• Schmidt MH, Berger MS, Lamborn KR et al. Repeated operations for infiltrative low-grade gliomas without intervening therapy. J. Neurosurg.98(6), 1165–1169 (2003).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Nicolardi L, Tosoni A et al. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro-Oncol.8(3), 253–260 (2006).
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Reardon D, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. Cancer110, 113–124 (2007).
   Google Scholar